G. Kearns, Patricia K. Robinson, John T. Wilson
Oct 1, 2003
Citations
2
Influential Citations
77
Citations
Quality indicators
Journal
Clinical Pharmacology & Therapeutics
Abstract
Cisapride, a prokinetic agent and substrate for cytochrome P450 (CYP) 3A4, has been used to treat neonates and infants with feeding intolerance and apnea or bradycardia associated with gastroesophageal reflux. At age 1 month, CYP3A4 activity has been reported to be only 30% to 40% of adult activity. This known developmental delay in the expression of CYP3A4 prompted us to conduct a classical open‐label pharmacokinetic study of cisapride in neonates and young infants.